Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Achilles Therapeutics stock | $12.63
Learn how to easily invest in Achilles Therapeutics stock.
Achilles Therapeutics plc is a biotechnology business based in the US. Achilles Therapeutics shares (ACHL) are listed on the NASDAQ and all prices are listed in US Dollars. Achilles Therapeutics employs 153 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Achilles Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ACHL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Achilles Therapeutics stock price (NASDAQ: ACHL)Use our graph to track the performance of ACHL stocks over time.
Achilles Therapeutics shares at a glance
|Latest market close||$12.63|
|52-week range||$5.76 - $18.95|
|50-day moving average||$9.30|
|200-day moving average||$12.20|
|Wall St. target price||$23.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Achilles Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Achilles Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Achilles Therapeutics price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||27.19%|
|3 months (2021-04-30)||-18.78%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Achilles Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-17.13%|
|Return on equity TTM||-29.78%|
|Market capitalisation||$245.8 million|
TTM: trailing 12 months
Shorting Achilles Therapeutics shares
There are currently 328,653 Achilles Therapeutics shares held short by investors – that's known as Achilles Therapeutics's "short interest". This figure is 13% up from 290,776 last month.
There are a few different ways that this level of interest in shorting Achilles Therapeutics shares can be evaluated.
Achilles Therapeutics's "short interest ratio" (SIR)
Achilles Therapeutics's "short interest ratio" (SIR) is the quantity of Achilles Therapeutics shares currently shorted divided by the average quantity of Achilles Therapeutics shares traded daily (recently around 52167.142857143). Achilles Therapeutics's SIR currently stands at 6.3. In other words for every 100,000 Achilles Therapeutics shares traded daily on the market, roughly 6300 shares are currently held short.
To gain some more context, you can compare Achilles Therapeutics's short interest ratio against those of similar companies.
However Achilles Therapeutics's short interest can also be evaluated against the total number of Achilles Therapeutics shares, or, against the total number of tradable Achilles Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Achilles Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Achilles Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.112% of the tradable shares (for every 100,000 tradable Achilles Therapeutics shares, roughly 112 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Achilles Therapeutics.
Find out more about how you can short Achilles Therapeutics stock.
Achilles Therapeutics share dividends
We're not expecting Achilles Therapeutics to pay a dividend over the next 12 months.
Achilles Therapeutics overview
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom. .
Stocks similar to Achilles Therapeutics
Achilles Therapeutics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Is Achilles Therapeutics plc (ACHL) A Good Stock To Buy?
Frequently asked questionsWhat percentage of Achilles Therapeutics is owned by institutions?
Currently 47.057% of Achilles Therapeutics shares are held by institutions. How many people work for Achilles Therapeutics?
Latest data suggests 153 work at Achilles Therapeutics. When does the fiscal year end for Achilles Therapeutics?
Achilles Therapeutics's fiscal year ends in December. Where is Achilles Therapeutics based?
Achilles Therapeutics's address is: 245 Hammersmith Road, London, United Kingdom, W6 8PW
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert